Systematic review / meta-analysis / 2020
A systematic review indicates NAD+ precursors show favorable outcomes in age-related disorders, but long-term human trial evidence remains limited.
A systematic review evaluated the potential health and longevity benefits of increasing NAD+ levels across Medline, Embase, and PubMed. A total of 147 articles (113 preclinical and 34 clinical) met the inclusion criteria. Most studies reported that NAD+ precursors (NAM, NR, NMN, and to a lesser extent NAD+ and NADH) showed favorable outcomes on several age-related disorders tied to oxidative stress, inflammation, and mitochondrial impairment. However, evidence remains quite limited, long-term human trials are nascent, and potential risks include the accumulation of toxic metabolites, tumorigenesis, and cellular senescence.
- Study type
- Systematic review
- Who was studied
- 147 included articles (113 preclinical and 34 clinical)
- What was measured
- Health and/or longevity benefits and safety of raising NAD+ levels
THE PAPER
NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis.
Braidy N, Liu Y. Exp Gerontol, 2020.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.